In September 2009, Nycomed announced plans to build a production plant in Russia, with a total investment of between 65 million and 75 million euros (US$96 million and US$110 million).
The new site will be located in Yaroslavl, around 280 kilometres from Moscow, and construction will start there in 2010. The factory will have a total of 150 employees when production begins in 2014.
The new facility will manufacture medicines for the Russian and neighbouring markets of the Commonwealth of Independent States (CIS), which together account for 10% of Nycomed’s turnover.
Production taking place at the plant will include liquid sterile products such as ampoules and vials, as well as tablets. It will also manufacture products which are important for the local market, such as Cardiomagnyl (acetylsalicyclic acid and magnesium hydroxide) for pain relief, the bovine blood derivative Actovegin and the anticoagulant warfarin.
Further reading - An in-depth review of the Russian pharmaceutical market, including some background information on local manufacturers, is available from Espicom: The Pharmaceutical Market: Russia (published June 2009)